Meta-analysis of flecainide safety in patients with supraventricular arrhythmias

Arzneimittel-Forschung/Drug Research

Volumn 52, Issue 7, 2002, Pages 507-514

  Wehling, Martin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Antiarrhythmic drugs; Arrhythmia, supraventricular; CAS 54143 55 4; Flecainide, safety

Indexed keywords

FLECAINIDE;

ANGINA PECTORIS; ATRIOVENTRICULAR BLOCK; CANCER; CAUSE OF DEATH; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DYSPNEA; HEART DEATH; HEART FAILURE; HEART PALPITATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPOTENSION; META ANALYSIS; MORTALITY; NAUSEA; NEUROTOXICITY; REVIEW; SEPSIS; SINUS NODE DISEASE; SUICIDE; SYNCOPE; VERTIGO;

EID: 0036071081     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1299923     Document Type: Review

References (13)

1. Epidemiology and significance of atrial fibrillation
2. Predictors of thromboembolism in atrial fibrillation, I. Clinical features of patients at risk
3. Follow-up of atrial fibrillation. The initial experience of the Canadian Registry of Atrial Fibrillation
4. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial
5. Epidemiology and classification of atrial fibrillation
6. Improving the quality of reports of meta-analyses of randomized controlled trials: The QUOROM statement
7. Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias
8. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter
9. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
11. Deaths: Final data for 1998
12. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias